A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy

Hyun Il Cho, Eduardo Reyes-Vargas, Julio C. Delgado, Esteban Celis

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Adoptive cell therapy using tumor-reactive T lymphocytes is a promising approach for treating advanced cancer. Successful tumor eradication depends primarily on the expansion and survival of the adoptively transferred T cells. Lymphodepletion using total body irradiation (TBI) and administering high-dose interleukin (IL)-2 have been used with adoptive cell therapy to promote T-cell expansion and survival to achieve maximal therapeutic effects. However, TBI and high-dose IL-2 increase the risk formajor complications that impact overall survival. Here we describe an alternative approach to TBI and high-dose IL-2 for optimizing adoptive cell therapy, resulting in dramatic therapeutic effects against established melanomas in mice. Administration of a potent, noninfectious peptide vaccine after adoptive cell therapy dramatically increased antigen-specific T-cell numbers leading to enhancement in the survival of melanoma-bearing mice. Furthermore, combinations of peptide vaccination with PD1 blockade or IL-2/anti-IL-2 antibody complexes led to complete disease eradication and long-term survival in mice with large tumors receiving adoptive cell therapy. Our results indicate that PD1 blockade and IL-2/anti-IL-2 complexes enhance both the quantitative and qualitative aspects of the T-cell responses induced by peptide vaccination after adoptive cell therapy. These findings could be useful for the optimization of adoptive cell therapy in cancer patients without the need of toxic adjunct procedures.

Original languageEnglish (US)
Pages (from-to)1986-1995
Number of pages10
JournalCancer Research
Volume72
Issue number8
DOIs
StatePublished - Apr 15 2012

Fingerprint

Cell- and Tissue-Based Therapy
Interleukin-2
Vaccination
T-Lymphocytes
Whole-Body Irradiation
Therapeutic Uses
Neoplasms
Survival
Melanoma
Disease Eradication
Peptides
Subunit Vaccines
Poisons
Cell Survival
Cell Count
Antigens
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. / Cho, Hyun Il; Reyes-Vargas, Eduardo; Delgado, Julio C.; Celis, Esteban.

In: Cancer Research, Vol. 72, No. 8, 15.04.2012, p. 1986-1995.

Research output: Contribution to journalArticle

Cho, Hyun Il ; Reyes-Vargas, Eduardo ; Delgado, Julio C. ; Celis, Esteban. / A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. In: Cancer Research. 2012 ; Vol. 72, No. 8. pp. 1986-1995.
@article{b3833d995b58426b80253c376db362f6,
title = "A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy",
abstract = "Adoptive cell therapy using tumor-reactive T lymphocytes is a promising approach for treating advanced cancer. Successful tumor eradication depends primarily on the expansion and survival of the adoptively transferred T cells. Lymphodepletion using total body irradiation (TBI) and administering high-dose interleukin (IL)-2 have been used with adoptive cell therapy to promote T-cell expansion and survival to achieve maximal therapeutic effects. However, TBI and high-dose IL-2 increase the risk formajor complications that impact overall survival. Here we describe an alternative approach to TBI and high-dose IL-2 for optimizing adoptive cell therapy, resulting in dramatic therapeutic effects against established melanomas in mice. Administration of a potent, noninfectious peptide vaccine after adoptive cell therapy dramatically increased antigen-specific T-cell numbers leading to enhancement in the survival of melanoma-bearing mice. Furthermore, combinations of peptide vaccination with PD1 blockade or IL-2/anti-IL-2 antibody complexes led to complete disease eradication and long-term survival in mice with large tumors receiving adoptive cell therapy. Our results indicate that PD1 blockade and IL-2/anti-IL-2 complexes enhance both the quantitative and qualitative aspects of the T-cell responses induced by peptide vaccination after adoptive cell therapy. These findings could be useful for the optimization of adoptive cell therapy in cancer patients without the need of toxic adjunct procedures.",
author = "Cho, {Hyun Il} and Eduardo Reyes-Vargas and Delgado, {Julio C.} and Esteban Celis",
year = "2012",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-11-3246",
language = "English (US)",
volume = "72",
pages = "1986--1995",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy

AU - Cho, Hyun Il

AU - Reyes-Vargas, Eduardo

AU - Delgado, Julio C.

AU - Celis, Esteban

PY - 2012/4/15

Y1 - 2012/4/15

N2 - Adoptive cell therapy using tumor-reactive T lymphocytes is a promising approach for treating advanced cancer. Successful tumor eradication depends primarily on the expansion and survival of the adoptively transferred T cells. Lymphodepletion using total body irradiation (TBI) and administering high-dose interleukin (IL)-2 have been used with adoptive cell therapy to promote T-cell expansion and survival to achieve maximal therapeutic effects. However, TBI and high-dose IL-2 increase the risk formajor complications that impact overall survival. Here we describe an alternative approach to TBI and high-dose IL-2 for optimizing adoptive cell therapy, resulting in dramatic therapeutic effects against established melanomas in mice. Administration of a potent, noninfectious peptide vaccine after adoptive cell therapy dramatically increased antigen-specific T-cell numbers leading to enhancement in the survival of melanoma-bearing mice. Furthermore, combinations of peptide vaccination with PD1 blockade or IL-2/anti-IL-2 antibody complexes led to complete disease eradication and long-term survival in mice with large tumors receiving adoptive cell therapy. Our results indicate that PD1 blockade and IL-2/anti-IL-2 complexes enhance both the quantitative and qualitative aspects of the T-cell responses induced by peptide vaccination after adoptive cell therapy. These findings could be useful for the optimization of adoptive cell therapy in cancer patients without the need of toxic adjunct procedures.

AB - Adoptive cell therapy using tumor-reactive T lymphocytes is a promising approach for treating advanced cancer. Successful tumor eradication depends primarily on the expansion and survival of the adoptively transferred T cells. Lymphodepletion using total body irradiation (TBI) and administering high-dose interleukin (IL)-2 have been used with adoptive cell therapy to promote T-cell expansion and survival to achieve maximal therapeutic effects. However, TBI and high-dose IL-2 increase the risk formajor complications that impact overall survival. Here we describe an alternative approach to TBI and high-dose IL-2 for optimizing adoptive cell therapy, resulting in dramatic therapeutic effects against established melanomas in mice. Administration of a potent, noninfectious peptide vaccine after adoptive cell therapy dramatically increased antigen-specific T-cell numbers leading to enhancement in the survival of melanoma-bearing mice. Furthermore, combinations of peptide vaccination with PD1 blockade or IL-2/anti-IL-2 antibody complexes led to complete disease eradication and long-term survival in mice with large tumors receiving adoptive cell therapy. Our results indicate that PD1 blockade and IL-2/anti-IL-2 complexes enhance both the quantitative and qualitative aspects of the T-cell responses induced by peptide vaccination after adoptive cell therapy. These findings could be useful for the optimization of adoptive cell therapy in cancer patients without the need of toxic adjunct procedures.

UR - http://www.scopus.com/inward/record.url?scp=84860191757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860191757&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-3246

DO - 10.1158/0008-5472.CAN-11-3246

M3 - Article

C2 - 22367213

AN - SCOPUS:84860191757

VL - 72

SP - 1986

EP - 1995

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -